The company's manufacturing model has historically relied on internal production at its Rensselaer, New York and Limerick, Ireland facilities, but the $9 billion infrastructure commitment announced in recent years includes expanding internal capacity and partnering with FUJIFILM Diosynth Biotechnologies through a $3 billion agreement to ensure sufficient supply for Dupixent, EYLEA HD, and pipeline candidates. The company's business model is therefore uniquely exposed to the commercial decisions of its partners: Sanofi's pricing strategy for Dupixent in Europe, Bayer's marketing investment for EYLEA in Japan, and the manufacturing efficiency achieved at shared facilities all directly impact Regeneron's reported revenue and operating income. The stock's valuation at 15.5 times trailing earnings reflects investor skepticism about EYLEA's biosimilar defense and Dupixent's patent longevity, even as the company continues to deliver 30% profit margins and industry-leading R&D efficiency. The COPD approval secured in 2024 and 2025 expands Dupixent's addressable market by an estimated $8-10 billion annually, but GSK's Nucala (mepolizumab) and AstraZeneca's Fasenra (benralizumab) have established eosinophil-targeted positions in severe asthma that may limit Dupixent's penetration in certain phenotypes. The company's strategy of avoiding head-to-head competition in saturated markets, as evidenced by Libtayo's focus on underserved tumor types and the GPR75 program's genetic validation approach, reflects a competitive discipline that prioritizes scientific differentiation over commercial scale. The second major challenge is the patent cliff facing Dupixent, which, despite achieving $17.8 billion in global sales for Sanofi in 2025 with 26% growth, faces composition of matter patent expirations in the late 2020s and early 2030s that will inevitably invite generic biologic competition, though the complexity of IL-4Rα blockade and the expanding indication portfolio may provide some defense through method-of-use patents and regulatory exclusivity. Finally, the pipeline diversification challenge remains acute: despite nearly 50 product candidates, no late-stage program has demonstrated the clear blockbuster potential required to replace EYLEA or Dupixent revenues, with candidates like itepekimab in COPD facing competitive markets already populated by GSK's Nucala and AstraZeneca's Fasenra, and odronextamab in lymphoma entering a bispecific antibody space crowded with Genmab's epcoritamab and Roche's glofitamab. This genetics-first approach reduces clinical trial risk by providing human genetic validation before Phase 1 dosing, a de-risking strategy that has attracted partnerships with Bayer, Sanofi, Intellia, and Alnylam. Regeneron's growth strategy for the 2025-2028 period is built on four parallel initiatives: indication expansion for existing franchises, pipeline commercialization, manufacturing capacity scaling, and new modality entry through selective acquisitions. EYLEA HD's growth strategy focuses on converting the remaining 63% of U.S. Patients still on original EYLEA to the high-dose 8mg formulation through real-world evidence generation showing reduced treatment burden from extended dosing intervals, while defending against Vabysmo and biosimilars through physician education and formulary contracting. The pipeline commercialization strategy targets four late-stage assets: odronextamab, a CD20xCD3 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma that could generate $1-2 billion in peak sales; fianlimab, a LAG-3 inhibitor in combination with Libtayo for metastatic melanoma; itepekimab, an IL-33 antibody for COPD in former smokers; and linvoseltamab, a BCMAxCD3 bispecific for multiple myeloma. The new modality strategy centers on Regeneron Cell Medicines, which absorbed 150 employees and multiple clinical programs from 2seventy bio, and the Decibel gene therapy platform, where DB-OTO has shown early clinical promise in providing physiological hearing to children with otoferlin mutations. Each initiative carries specific milestones: Dupixent COPD FDA approval in 2025, odronextamab FDA submission in 2025-2026, EYLEA HD pre-filled syringe approval in Q2 2026, and DB-OTO registration trial initiation by December 2028. Regeneron's strategic bet for the next three years centers on the successful transition of EYLEA HD from a niche high-dose option to the dominant anti-VEGF therapy in ophthalmology, the expansion of Dupixent into chronic obstructive pulmonary disease and chronic spontaneous urticaria to sustain immunology growth, and the commercialization of late-stage pipeline assets including odronextamab in lymphoma, fianlimab in metastatic melanoma, and itepekimab in COPD. The company's genetics-driven discovery engine continues to identify new targets, with the GPR75 loss-of-function variant program in obesity entering clinical development and the Regeneron Genetics Center expanding beyond exome sequencing to proteomics and multi-omics integration. International expansion represents a secondary growth vector, with Regeneron building direct commercial capabilities in European markets for Libtayo and exploring Asian partnerships for pipeline assets beyond the existing Sanofi and Bayer arrangements. The 2025 approval of DB-OTO as the first gene therapy for otoferlin-related congenital hearing loss establishes Regeneron in a new therapeutic modality, though the ultra-rare indication limits near-term revenue to tens of millions annually unless the platform expands to more common GJB2 and STRC mutations. The turning point came in the late 1990s and early 2000s when Regeneron developed a trap technology that fused receptor domains to antibody Fc regions, creating a novel class of biologics that would eventually yield EYLEA, a VEGF trap that blocks vascular endothelial growth factor with higher affinity than monoclonal antibodies. The EYLEA program, initially partnered with Bayer in 2003, progressed through clinical trials for wet age-related macular degeneration and received FDA approval in November 2011, transforming Regeneron from a perpetual development-stage company into a profitable commercial enterprise. The success of EYLEA validated the trap technology and provided the cash flow to fund the expansion of VelocImmune and the genetics center, while the 2007 Sanofi partnership, initially focused on cardiovascular disease, was restructured in 2015 to prioritize immunology, leading to the discovery and approval of Dupixent in 2017.